Protein / target

Replicase polyprotein 1ab

repP0DTD1Severe acute respiratory syndrome coronavirus 2Swiss-Prot
UniProt: P0DTD1NCBI Gene: 43740578
30
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

MRNA 5'-cap (guanine-N7-)-methyltransferase activity

Primary system

Immune system

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Multifunctional protein involved in the transcription and replication of viral RNAs. Contains the proteinases responsible for the cleavages of the polyprotein

Subcellular location

Host cytoplasmHost endosomeHost endoplasmic reticulum membraneHost Golgi apparatusHost nucleusHost cytoplasm, host perinuclear regionHost endoplasmic reticulumHost endoplasmic reticulum-Golgi intermediate compartment
Domains and Gene Ontology detail (80)

Domains & features

CoV Nsp1 globularBetaCoV Nsp1 C-terminalCoV Nsp2 N-terminalCoV Nsp2 middleCoV Nsp2 C-terminalUbiquitin-like 1Macro 1Macro 2Macro 3DPUPUbiquitin-like 2Peptidase C16Nucleic acid-bindingG2M3EctoCoV Nsp3 Y

Gene Ontology

  • Cdouble membrane vesicle viral factory outer membrane
  • Chost cell endoplasmic reticulum membrane
  • Chost cell endoplasmic reticulum-Golgi intermediate compartment
  • Chost cell endosome
  • Chost cell Golgi apparatus
  • Chost cell nucleus
  • Chost cell perinuclear region of cytoplasm
  • F3'-5'-RNA exonuclease activity
  • F5'-3' DNA helicase activity
  • F5'-3' RNA helicase activity
  • FATP binding
  • FATP hydrolysis activity

7096 aa · 794 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO · ReactomeImmune signallingGO · ReactomeProteolysisGOMetabolic enzyme activityGO
View supporting evidence

Transcriptional regulation

  • ·Multifunctional protein involved in the transcription and replication of viral RNAs. Con…
  • ·DNA-templated transcription
  • ·symbiont-mediated suppression of host gene expression
  • ·Assembly of the SARS-CoV-2 Replication-Transcription Complex (RTC)

Immune signalling

  • ·host cell endoplasmic reticulum membrane
  • ·host cell endoplasmic reticulum-Golgi intermediate compartment
  • ·host cell endosome
  • ·host cell Golgi apparatus

Proteolysis

  • ·cysteine-type endopeptidase activity
  • ·ISG15-specific peptidase activity
  • ·omega peptidase activity
  • ·proteolysis

Metabolic enzyme activity

  • ·mRNA 5'-cap (guanine-N7-)-methyltransferase activity
  • ·mRNA guanylyltransferase activity
  • ·protein guanylyltransferase activity
View underlying pathways (10)
snRNP Assembly
TRAF3-dependent IRF activation pathway
Viral strategies to evade IFIT action
Assembly of the SARS-CoV-2 Replication-Transcription Complex (RTC)
Maturation of replicase proteins
Translation of Replicase and Assembly of the Replication Transcription Complex
Replication of the SARS-CoV-2 genome
Transcription of SARS-CoV-2 sgRNAs
SARS-CoV-2 activates/modulates innate and adaptive immune responses
SARS-CoV-2 modulates host translation machinery

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

remdesivir
Narrow target profileInhibitor

Replicase polyprotein 1ab inhibitor

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized AdultsPHASE3

COMPLETED · via remdesivir · NCT04280705

The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes MellitusPHASE3

WITHDRAWN · via remdesivir · NCT04970719

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANYPHASE2/PHASE3

WITHDRAWN · via remdesivir · NCT04575064

Remdesivir Efficacy In Management Of COVID-19 PatientsPHASE3

COMPLETED · via remdesivir · NCT04853901

Comparative Therapeutic Efficacy and Safety of Remdesivir Plus Lopinavir/ Ritonavir and Tocilizumab Versus Hydroxychloroquine Plus Ivermectin and Tocilizumab in COVID-19 Patients.PHASE4

UNKNOWN · via remdesivir · NCT04779047

A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized AdultsPHASE2

COMPLETED · via remdesivir · NCT04988035

Show remaining trials (24)
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized AdultsPHASE3

COMPLETED · via remdesivir · NCT04315948

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial: the OPTICOV StudyPHASE2

RECRUITING · via remdesivir · NCT05587894

Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled TrialPHASE3

COMPLETED · via remdesivir · NCT04678739

Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19NA

COMPLETED · via remdesivir · NCT04492501

A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 PneumoniaPHASE3

COMPLETED · via remdesivir · NCT04409262

A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19PHASE2/PHASE3

COMPLETED · via remdesivir · NCT04431453

An Open-label Randomized Controlled Trial on Interferon β-1b and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 InfectionPHASE2

UNKNOWN · via remdesivir · NCT04647695

WHO Public Health Emergency "Solidarity" Clinical Trial for COVID-19 TreatmentsPHASE3

UNKNOWN · via remdesivir · NCT04647669

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19 (Trial H2: Remdesivir)PHASE3

COMPLETED · via remdesivir · NCT06729593

An Open-label, Randomized, Single Intravenous Dosing Study to Investigate the Effect of Fixed-dose Combinations of Tenofovir/Lamivudine or Atazanavir/Ritonavir on the Pharmacokinetics of Remdesivir in Ugandan Healthy VolunteersPHASE2

COMPLETED · via remdesivir · NCT04385719

Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled TrialPHASE2

COMPLETED · via remdesivir · NCT04596839

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care PhilippinesNA

COMPLETED · via remdesivir · NCT05024006

A Phase II Study to Evaluate the Safety, Pharmacokinetics, Antiviral Activity and Acceptability of Remdesivir (VEKLURY®) in Hospitalized Children Aged 0 to Less Than 2 Years With Respiratory Syncytial Virus (RSV)-Associated Lower Respiratory Tract Infection.PHASE2

RECRUITING · via remdesivir · NCT06873633

A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)PHASE3

COMPLETED · via remdesivir · NCT04640168

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H3: BRII-196/BRII-198)PHASE3

COMPLETED · via remdesivir · NCT05780424

A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 InfectionPHASE3

TERMINATED · via remdesivir · NCT04784559

Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of AREPLIVIR® (Favipiravir) for Parenteral Administration (PROMOMED RUS LLC, Russia) in Hospitalized Patients With COVID-19PHASE3

COMPLETED · via remdesivir · NCT05185284

Safety and Efficacy of 10-day Course of Remdesivir to Prevent Severe COVID-19 in Asymptomatic or Paucisymptomatic SARS-COV-2-positive Kidney Transplant Recipients: a Single-arm Proof-of-concept Interventional TrialPHASE2

RECRUITING · via remdesivir · NCT07197164

A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)PHASE3

COMPLETED · via remdesivir · NCT04401579

Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal: a Multi-center, Randomized, Open-labelled, Phase III Clinical TrialPHASE3

UNKNOWN · via remdesivir · NCT04694612

Efficacy of Ramdicivir and Baricitinib Combination Therapy for the Treatment of COVID 19 ARDSPHASE3

UNKNOWN · via remdesivir · NCT04693026

Effectiveness of Remedesvir in SARS-CoV2 Patients Presenting at Mayo Hospital LahoreNA

COMPLETED · via remdesivir · NCT04871633

A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)PHASE2/PHASE3

UNKNOWN · via remdesivir · NCT04351724

Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional StudyEARLY_PHASE1

UNKNOWN · via remdesivir · NCT04560231

ClinicalTrials.gov via the drug-target graph.

What's happening now

27

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Label change2026-07-29

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  2. Label change2025-10-07

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  3. Label change2025-08-22

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  4. Label change2025-01-10

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  5. Label change2024-12-19

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  6. Label change2024-06-27

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  7. Indication expanded2024-02-28

    Indication expansion: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  8. Label change2023-08-23

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  9. Label change2023-08-17

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  10. Indication expanded2023-07-13

    Indication expansion: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  11. Label change2023-06-12

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

  12. Label change2023-06-07

    Label change: REMDESIVIR (NDA214787)

    fda · regulatory · fda · via remdesivir

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.